Alcon Inc. Swiss: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
Builds on company s ophthalmic pharmaceutical manufacturing expertise
Regulatory News:
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to
Simbrinza
The acquisition of
Simbrinza combined with the company s existing over-the-counter (OTC) eye drops will give Alcon a strong ophthalmic eye drop portfolio and the opportunity to capitalize on both the large glaucoma market and the fast-growing dry eye preservative free and eye allergy markets. The company s strong U.S. ophthalmology expertise and existing relationships with healthcare professionals (HCP) will help drive HCP and patient adoption.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Alcon Shareholders Approve All Binding Resolutions at the 2021 Annual General Meeting
April 28, 2021 GMT
GENEVA (BUSINESS WIRE) Apr 28, 2021
Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the results of its 2021 Annual General Meeting.
Given the global COVID-19 outbreak, Alcon previously directed shareholders to send their voting instructions to the independent representative, Hartmann Dreyer Attorneys-at-Law.
Shareholders showed a high level of interest and engagement in the resolutions proposed, with a total of 347,227,434 Alcon Inc. shares, corresponding to 70.87% of the shares entitled to vote, represented.
Alcon Inc. Investors: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza
Builds on company s ophthalmic pharmaceutical manufacturing expertise
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to
Simbrinza
The acquisition of
Simbrinza combined with the company s existing over-the-counter (OTC) eye drops will give Alcon a strong ophthalmic eye drop portfolio and the opportunity to capitalize on both the large glaucoma market and the fast-growing dry eye preservative free and eye allergy markets. The company s strong U.S. ophthalmology expertise and existing relationships with healthcare professionals (HCP) will help drive HCP and patient adoption.
Alcon to Acquire U S Commercialization Rights to Ophthalmic Eye Drop Simbrinza apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Alcon Inc. Investors: Alcon Reports Fourth Quarter and Full Year 2020 Results
Continued recovery resulted in full year sales of $6.8 billion, 8% below last year
New product launches driving market share gains; executing on strategic initiatives
Generated $823 million in cash from operations and $350 million in free cash flow
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the fourth quarter and full year ended December 31, 2020. For the fourth quarter of 2020, worldwide sales were $1.9 billion, an increase of 2% on a reported basis and an increase of 1% on a constant currency basis
(2), as compared to the same quarter of the previous year. Fourth quarter 2020 diluted earnings per share were $0.19 and core diluted earnings per share were $0.41. Full year 2020 diluted losses per share were $1.09 and core diluted earnings per share were $1.04.